🤝 The deal includes process development, technology transfer, and clinical manufacturing of CAR-T cell therapies.
💡 ViroCell’s expertise in cell manufacturing will support UCL’s research and development efforts in the field.
🏥 This collaboration aims to accelerate the development of CAR-T cell therapies for the treatment of cancer.
💉 CAR-T cell therapy is a promising approach that involves modifying a patient’s own immune cells to target and kill cancer cells.
Introduction:
This article discusses the partnership between ViroCell and University College London (UCL) for the manufacturing of chimeric antigen receptor T-cell (CAR-T) therapies. CAR-T therapies are a type of immunotherapy that use genetically engineered T cells to treat cancer. ViroCell will provide manufacturing capabilities and expertise to support UCL’s CAR-T therapy development program.
- ViroCell, a contract development and manufacturing organization (CDMO), has entered into a manufacturing agreement with UCL for CAR-T therapies.
- CAR-T therapies involve the modification of a patient’s own T cells to express receptors that can target and kill cancer cells.
- ViroCell will provide process development, cell banking, and manufacturing services to support UCL’s CAR-T therapy development program.
- The collaboration aims to accelerate the development and commercialization of CAR-T therapies and improve patient access to these innovative treatments.
- This partnership highlights the growing importance of CDMOs in supporting the manufacture of advanced therapies and the potential of CAR-T therapies as a promising approach for the treatment of cancer.
Conclusion:
In collaboration with UCL, ViroCell will provide manufacturing capabilities and expertise to support the development of CAR-T therapies. This partnership aims to accelerate the development and commercialization of these innovative therapies, which have shown promising results in the treatment of cancer. The involvement of a CDMO like ViroCell highlights the increasing importance of outsourcing manufacturing services for advanced therapies. This partnership has the potential to improve patient access to CAR-T therapies and contribute to advancements in the field of cancer treatment.
